Clinical
British Journal of Cancer (2004) 90, 306–309. doi:10.1038/sj.bjc.6601521 www.bjcancer.com
Published online 20 January 2004
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
R Petrioli1, M Sabatino1, A I Fiaschi2, S Marsili1, D Pozzessere1, S Messinese1, P Correale1, S Civitelli3, G Tanzini3, F Tani4, A De Martino4, G Marzocca4, M Lorenzi4, G Giorgi2 and G Francini1
- 1Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
- 2Department of Pharmacology, University of Siena, Siena, Italy
- 3Clinical Surgery; University of Siena, Siena, Italy
- 4General Surgery; University of Siena, Siena, Italy
Correspondence: G Francini, E-mail: francini@unisi.it
Received 28 July 2003; Revised 23 October 2003; Accepted 23 October 2003.
Abstract
A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
Keywords:
colorectal cancer, irinotecan, oxaliplatin, tegafur/uracil
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
